PEARKO Therapeutics Inc.

PEARKO Therapeutics Inc. is a biopharmaceutical company engaged in the practice of translational medicine working to drive the translation of molecular discoveries to patients. We are primarily focused on novel and innovative therapies for cardiovascular diseases as these carry a significant physical and financial burden on patients and our healthcare systems. Cardiovascular disease remains the leading cause of death worldwide. PEARKO Therapeutics intends to address these critical medical challenges by providing pharmacological therapies to patients with cardiovascular disease through innovative technologies. PEARKO Therapeutics has established itself in the field of biopharmaceuticals with its innovative and proprietary biologic, Apelin Analog therapy, as a treatment for patients with heart failure, myocardial infarction (heart attack), and pulmonary arterial hypertension. This unique analog acts as a substitute to the innate apelin peptide, which is downregulated in cardiovascular disease. Apelin Analog therapy works to promote the activation of protective pathways in the cardiovascular system, which ultimately serves to improve patient outcomes and quality of life through a promoted recovery process. Our patented formulations are more stable and longer-lasting than the innate peptide and bioactive for over 24 hours, as opposed to minutes. PEARKO Therapeutics continues to push the boundaries of therapies for cardiovascular disease with an exciting pipeline of biologics.